Fig 1: Western blot analysis of expression of IDH2, SLC7A8, SCP2, and COL4A2 proteins in the mammary gland of cows fed corn stover (CS) and alfalfa hay (AH). β-Actin was used as a sample loading control. ** and * indicate p < 0.01 and 0.01 < p < 0.05, respectively. IDH2: Isocitrate dehydrogenase 2; SLC7A8: also referred as LAT2, L type amino acid transporter 2; SCP2: sterol carrier protein 2; COL4A2: collagen type IV alpha 2
Fig 2: Acquired resistance mutation of SLC7A8.(A) Venn diagram of acquired mutation in PR and PD patients. (B) Schematic of SLC7A8 somatic mutation in this ESCC cohort. Only 1 mutation was identified from treatment-specific samples. (C) Cancer cell fraction (CCF) of SLC7A8 p.T184P across PR and PD patients. (D) Private branch contained SLC7A8 p.T184P and is illustrated in the phylogenetic tree of patient PD_P2.
Fig 3: Summary of the microbiota–gut–brain axis in the CHD8 mouse model of ASD.Chd8+/− mice show increased expression of the intestinal transporters SLC6A19 and SLC7A8, resulting in more glutamine transported to the serum. Elevated serum glutamine increases the levels of glutamine and glutamate in the brain, contributing to the E/I imbalance and ASD-like behaviors in the Chd8+/− mice. Gut microbiota dysbiosis characterized by a low abundance of Bacteroides in the Chd8+/− mice is induced by high levels of intestinal α-defensins. In addition, supplementation with B. uniformis improves the E/I imbalance and restores ASD-like behaviors in the Chd8+/− mice by decreasing the intestinal amino acid transport of glutamine and thus reducing the glutamine and glutamate levels in the brain.
Fig 4: Expression of glutamine [LAT1 (A), LAT2 (B), SNAT5 (C)] and glutamate [EAAT1 (D), EAAT2 (E)] transporter proteins in membrane‐enriched placental homogenates [expressed as percentage of P0 versus wild‐type littermates (WTL)] at embryonic day (E)15.5 (N = 8) and E18.5 (N = 6/8)Densitometric analysis is expressed as a ratio of β‐tubulin signal. F, representative Western blots of LAT1, LAT2, SNAT5, EAAT1 and EAAT2 at E15.5 and E18.5 with the corresponding housekeeper protein. Black line = median; dotted line 100% = WTL placenta. * P < 0.05; Wilcoxon signed‐rank test versus 100%.
Fig 5: Validation of the genes in the prognostic signature. (A–I) Western blot for detection of the protein expression of (B) RCN1, (C) DNAJA2, (D) LASP1, (E) IBSP, (F) LAT2, (G) FUZ, (H) HOOK2, and (I) DAPK2 in laryngeal cancer and normal tissues. (J–Q) RT-qPCR for detecting the mRNA expression of (J) RCN1, (K) DNAJA2, (L) LASP1, (M) IBSP, (N) LAT2, (O) FUZ, (P) HOOK2, and (Q) DAPK2 in laryngeal cancer and normal tissues. Ns, not significant; *P < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Supplier Page from Abcam for Anti-LAT2 antibody